Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three ...